

Development of Novel Agents for Idiopathic Pulmonary Fibrosis: Phase 2a Clinical Trial and phase 2b approval of BBT-877, autotaxin inhibitor, in IPF patients

Bridge Biotherapeutics, Inc.



RESPIRATORY	Phase 2
Product Type	Small molecule
Indication	Idiopathic Pulmonary Fibrosis (IPF)
Target	Autotaxin (ATX)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> The ATX-LPA-LPAR axis has been suggested to play a pivotal role in the pathogenesis and the progression of IPF. BBT-877 binds to the catalytic domain of ATX, resulting in the inhibiting generation of PLA.
Competitiveness	<ul style="list-style-type: none"> Most significant and sustained LPA inhibition effect compared to competitors(as determined by blood LPA as a biomarker in phase 1 clinical trials)
Development Stage	Phase 2
Route of Administration	Oral